Oncotarget

Reviews:

Ras and autophagy in cancer development and therapy.

Eran Schmukler, Yoel Kloog and Ronit Pinkas-Kramarski _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:577-586. https://doi.org/10.18632/oncotarget.1775

Metrics: PDF 2398 views  |   HTML 2978 views  |   ?  


Abstract

Eran Schmukler1, Yoel Kloog1 and Ronit Pinkas-Kramarski1

1 Department of Neurobiology. Tel-Aviv University, Ramat-Aviv, Israel.

Correspondence:

Pinkas-Kramarski Ronit, email:

Keywords: Autophagy, Ras, cancer, oncogene

Received: January 6, 2014 Accepted: February 13, 2014 Published: February 13, 2014

Abstract

Autophagy, a process of self-degradation and turnover of cellular components, plays a complex role in cancer. Evidence exists to show that autophagy may support tumor growth and cell survival, whereas it can also contribute to tumor suppression and have anti-survival characteristics in different cellular systems. Numerous studies have described the effects of various oncogenes and tumor suppressors on autophagy. The small GTPase Ras is an oncogene involved in the regulation of various cell-signaling pathways, and is mutated in 33% of human cancers. In the present review, we discuss the interplay between Ras and autophagy in relation to oncogenesis. It appears that Ras can upregulate or downregulate autophagy through several signaling pathways. In turn, autophagy can affect the tumorigenicity driven by Ras, resulting in either tumor progression or repression, depending on the cellular context. Furthermore, Ras inhibitors were shown to induce autophagy in several cancer cell lines.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1775